Anti-KMT2G / hSET1B antibody (ab113984)

Overview

  • Product nameAnti-KMT2G / hSET1B antibody
    See all KMT2G / hSET1B primary antibodies
  • Description
    Rabbit polyclonal to KMT2G / hSET1B
  • Tested applicationsSuitable for: IHC-P, WB, IPmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Rabbit, Cow, Chimpanzee, Gorilla
  • Immunogen

    Synthetic peptide corresponding to Human KMT2G/ hSET1B aa 350-400.
    Database link: 23067

  • Positive control
    • HeLa cell lysate

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
  • Storage bufferPreservative: 0.09% Sodium azide
    Constituent: 99% Tris citrate/phosphate
    Note: pH 7 to 8
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Purification notesab113984 is affinity purified using an epitope specific to KMT2G / hSET1B immobilized on solid support.
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas

Associated products

Applications

Our Abpromise guarantee covers the use of ab113984 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/500 - 1/2000. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB Use at an assay dependent concentration.

ab113984 has not performed satisfactorily when used for WB of KMT2G / hSET1B in crude preparations (e.g. whole cell lysate). This antibody can be used for WB of enriched (e.g. immunoprecipitated) sources of KMT2G / hSET1B.

IP Use at 10 µg/mg of lysate.

Target

  • FunctionHistone methyltransferase that specifically methylates 'Lys-4' of histone H3, when part of the SET1 histone methyltransferase (HMT) complex, but not if the neighboring 'Lys-9' residue is already methylated. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. The non-overalpping localization with SETD1A suggests that SETD1A and SETD1B make non-redundant contributions to the epigenetic control of chromatin structure and gene expression. Specifically tri-methylates 'Lys-4' of histone H3 in vitro.
  • Sequence similaritiesContains 1 post-SET domain.
    Contains 1 RRM (RNA recognition motif) domain.
    Contains 1 SET domain.
  • Cellular localizationNucleus speckle. Chromosome. Localizes to a largely non-overlapping set of euchromatic nuclear speckles with SETD1A, suggesting that SETD1A and SET1B each bind to a unique set of target genes.
  • Information by UniProt
  • Database links
  • Alternative names
    • FLJ20803 antibody
    • Histone-lysine N-methyltransferase SETD1B antibody
    • hSET1B antibody
    • KIAA1076 antibody
    • KMT2G antibody
    • Lysine N-methyltransferase 2G antibody
    • SET domain containing 1B antibody
    • SET domain-containing protein 1B antibody
    • SET1B antibody
    • SET1B_HUMAN antibody
    • SETD1B antibody
    see all

Anti-KMT2G / hSET1B antibody images

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human ovarian carcinoma tissue labelling KMT2G / hSET1B with ab113984 at 1/1000 (1µg/ml). Detection: DAB.
  • ab113984 used at 10 µg/mg of lysate staining KMT2G / hSET1B in HeLa whole cell lysate (1 mg for IP, 20% of IP loaded) by immunoprecipitation. For blotting immunoprecipitated KMT2G / hSET1B, ab113984 was used at 1 µg/ml.

    Detection: Chemiluminescence with an exposure time of 3 minutes.

References for Anti-KMT2G / hSET1B antibody (ab113984)

ab113984 has not yet been referenced specifically in any publications.

Product Wall

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (HeLa)
Permeabilization Yes - 0.5% TritonX100 in PBS
Specification HeLa
Fixative Paraformaldehyde
Username

Dr. Kirk McManus

Verified customer

Submitted Jun 19 2015

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"